News
The FDA approval of lenacapavir as a form of preexposure prophylaxis (PrEP) is a major step for HIV prevention, but its ...
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...
Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...
1don MSN
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...
LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...
Kenya has been selected as one of the 9 early adopter countries for the rollout of Lenacapavir (LEN), a long-acting ...
Explore more
WHO director general Tedros Adhanom Ghebreyesus says this new drug—which only needs to be injected twice a year—is the next ...
16h
TheHealthSite on MSNWhat Is Lenacapavir? All About WHO Recommended Biannual HIV Prevention DrugA breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...
Lenacapavir, which was approved by the United States' Food and Drug Administration in June this year, is taken twice per year ...
GENEVA, 15 July 2025–Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV ...
Lenacapavir-a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences-is now recommended by the World Health ...
The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results